Clinical Trials in Philadelphia

Showing 6681-6700 of 20,904 trials

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

NCT04305444

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.

Relapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaDiffuse Large B Cell Lymphoma+2 more

Zhejiang DTRM Biopharma55 participantsStarted Apr 2020

Phoenix, Arizona, United States • New Haven, Connecticut, United States • Jacksonville, Florida, United States +5 more locations

COMPLETEDNA< 1 mile

FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

NCT03490201

This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.

Ventricular Tachycardia

Abbott Medical Devices592 participantsStarted Jun 2018

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Los Angeles, California, United States +29 more locations

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

Find Trials by Condition in Philadelphia

A Prospective Evaluation of Infraorbital Filler Injection

Liver Cancer Community Education

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

ACT with NMOSD Patients and Caregivers Pilot Study

Benefits of Microcor in Ambulatory Decompensated Heart Failure

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Benefits of µCor in Ambulatory Decompensated Heart Failure

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma